Targeting TBP-associated factors in ovarian cancer

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Ribeiro, Jennifer R ^a   Lovasco, Lindsay A ^b   Vanderhyden, Barbara C ^c,d   Freiman, Richard N ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Differentiation; Ovarian cancer; TAF2; TAF4; TAF4B; TAF9; TBP associated factors; TFIID

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR; PROTEIN P53; RNA POLYMERASE II; TAF4B PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TATA BINDING PROTEIN ASSOCIATED FACTOR 1; TATA BINDING PROTEIN ASSOCIATED FACTOR 10; TATA BINDING PROTEIN ASSOCIATED FACTOR 2; TATA BINDING PROTEIN ASSOCIATED FACTOR 4; TATA BINDING PROTEIN ASSOCIATED FACTOR 9; TRANSCRIPTION FACTOR IID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

EID: 84901014283     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00045     Document Type: Article

References (130)

1. McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer (2003) 89(Suppl 3):S3-8. doi: 10.1038/sj.bjc.6601494.
2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 2(5):401-4. doi:10.1158/2159-8290.CD-12-0095.
3. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 6(269):l1. doi:10.1126/scisignal.2004088.
4. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 9(3):167-81. doi:10.1038/nrc2583.
5. Sawadogo M, Roeder RG. Factors involved in specific transcription by human RNA polymerase II: analysis by a rapid and quantitative in vitro assay. Proc Natl Acad Sci U S A (1985) 82(13):4394-8. doi:10.1073/pnas.82.13.4394.
6. Reinberg D, Horikoshi M, Roeder RG. Factors involved in specific transcription in mammalian RNA polymerase II. Functional analysis of initiation factors IIA and IID and identification of a new factor operating at sequences downstream of the initiation site. J Biol Chem (1987) 262(7):3322-30.
7. Dynlacht BD, Hoey T, Tjian R. Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell (1991) 66(3):563-76. doi:10.1016/0092-8674(81)90019-2.
8. Kokubo T, Gong DW, Wootton JC, Horikoshi M, Roeder RG, Nakatani Y. Molecular cloning of Drosophila TFIID subunits. Nature (1994) 367(6462):484-7. doi:10.1038/367484a0.
9. Malkowska M, Kokoszynska K, Rychlewski L, Wyrwicz L. Structural bioinformatics of the general transcription factor TFIID. Biochimie (2013) 95(4):680-91. doi:10.1016/j.biochi.2012.10.024.
10. Müller FZA, Tora L. Developmental regulation of transcription initiation: more than just changing the actors. Curr Opin Genet Dev (2010) 20(5):533-40. doi:10.1016/j.gde.2010.06.004.
11. Deato MD, Marr MT, Sottero T, Inouye C, Hu P, Tjian R. MyoD targets TAF3/TRF3 to activate myogenin transcription. Mol Cell (2008) 32(1):96-105. doi:10.1016/j.molcel.2008.09.009.
12. Deato MD, Tjian R. Switching of the core transcription machinery during myogenesis. Genes Dev (2007) 21(17):2137-49. doi:10.1101/gad.1583407.
13. Deato MD, Tjian R. An unexpected role of TAFs and TRFs in skeletal muscle differentiation: switching core promoter complexes. Cold Spring Harb Symp Quant Biol (2008) 73:217-25. doi:10.1101/sqb.2008.73.028.
14. Dikstein R, Zhou S, Tjian R. Human TAFII 105 is a cell type-specific TFIID subunit related to hTAFII130. Cell (1996) 87(1):137-46. doi:10.1016/S0092-8674(00)81330-6.
15. Martianov I, Brancorsini S, Gansmuller A, Parvinen M, Davidson I, Sassone-Corsi P. Distinct functions of TBP and TLF/TRF2 during spermatogenesis: requirement of TLF for heterochromatic chromocenter formation in haploid round spermatids. Development (2002) 129(4):945-55.
16. Zhou H, Grubisic I, Zheng K, He Y, Wang PJ, Kaplan T, et al. Taf7l cooperates with Trf2 to regulate spermiogenesis. Proc Natl Acad Sci U S A (2013) 110(42):16886-91. doi:10.1073/pnas.1317034110.
17. Freiman RN, Albright SR, Zheng S, Sha WC, Hammer RE, Tjian R. Requirement of tissue-selective TBP-associated factor TAFII105 in ovarian development. Science (2001) 293(5537):2084-7. doi:10.1126/science.1061935.
18. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 110(8):2916-21. doi:10.1073/pnas.1222577110.
19. Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave M, et al. TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. Mol Endocrinol (2010) 24(4):696-708. doi:10.1210/me.2009-0229.
20. Kimura J, Nguyen ST, Liu H, Taira N, Miki Y, Yoshida K. A functional genome-wide RNAi screen identifies TAF1 as a regulator for apoptosis in response to genotoxic stress. Nucleic Acids Res (2008) 36(16):5250-9. doi:10.1093/nar/gkn506.
21. Centeno F, Ramirez-Salazar E, Garcia-Villa E, Gariglio P, Garrido E. TAF1 interacts with and modulates human papillomavirus 16 E2-dependent transcriptional regulation. Intervirology (2008) 51(2):137-43. doi:10.1159/000141706.
22. Carrillo E, Garrido E, Gariglio P. Specific in vitro interaction between papillomavirus E2 proteins and TBP-associated factors. Intervirology (2004) 47(6):342-9. doi:10.1159/000080878.
23. Allende-Vega N, Saville MK, Meek DW. Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53. Oncogene (2007) 26(29):4234-42. doi:10.1038/sj.onc.1210209.
24. Li HH, Li AG, Sheppard HM, Liu X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell (2004) 13(6):867-78. doi:10.1016/S1097-2765(04)00123-6.
25. Hilton TL, Li Y, Dunphy EL, Wang EH. TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. Mol Cell Biol (2005) 25(10):4321-32. doi:10.1128/MCB.25.10.4321-4332.2005.
26. Buchmann AM, Skaar JR, DeCaprio JA. Activation of a DNA damage checkpoint response in a TAF1-defective cell line. Mol Cell Biol (2004) 24(12):5332-9. doi:10.1128/MCB.24.12.5332-5339.2004.
27. Dehm SM, Hilton TL, Wang EH, Bonham K. SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol Cell Biol (2004) 24(6):2296-307. doi:10.1128/MCB.24.6.2296-2307.2004.
28. Bartusel T, Klempnauer KH. Transactivation mediated by B-Myb is dependent on TAF(II)250. Oncogene (2003) 22(19):2932-41. doi:10.1038/sj.onc.1206494.
29. Lively TN, Ferguson HA, Galasinski SK, Seto AG, Goodrich JA. c-Jun binds the N terminus of human TAF(II)250 to derepress RNA polymerase II transcription in vitro. J Biol Chem (2001) 276(27):25582-8. doi:10.1074/jbc.M100278200.
30. Wang EH, Zou S, Tjian R. TAFII250-dependent transcription of cyclin A is directed by ATF activator proteins. Genes Dev (1997) 11(20):2658-69. doi:10.1101/gad.11.20.2658.
31. Walker SS, Shen WC, Reese JC, Apone LM, Green MR. Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state. Cell (1997) 90(4):607-14. doi:10.1016/S0092-8674(00)80522-X.
32. Fadloun A, Kobi D, Pointud JC, Indra AK, Teletin M, Bole-Feysot C, et al. The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis. Development (2007) 134(16):2947-58. doi:10.1242/dev.005041.
33. Wardell JR, Hodgkinson KM, Binder AK, Seymour KA, Korach KS, Vanderhyden BC, et al. Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors. Biol Reprod (2013) 89(5):116. doi:10.1095/biolreprod.113.111336.
34. Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom RC, Roberg K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther (2010) 10(12):1244-51. doi:10.4161/cbt.10.12.13432.
35. Kalogeropoulou M, Voulgari A, Kostourou V, Sandaltzopoulos R, Dikstein R, Davidson I, et al. TAF4b and Jun/activating protein-1 collaborate to regulate the expression of integrin alpha6 and cancer cell migration properties. Mol Cancer Res (2010) 8(4):554-68. doi:10.1158/1541-7786.MCR-09-0159.
36. Teye K, Okamoto K, Tanaka Y, Umata T, Ohnuma M, Moroi M, et al. Expression of the TAF4b gene is induced by MYC through a non-canonical, but not canonical, E-box which contributes to its specific response to MYC. Int J Oncol (2008) 33(6):1271-80. doi:10.3892/ijo_00000118.
37. Wang W, Nahta R, Huper G, Marks JR. TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Mol Cancer Res (2004) 2(8):442-52.
38. Bell B, Scheer E, Tora L. Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function. Mol Cell (2001) 8(3):591-600. doi:10.1016/S1097-2765(01)00325-2.
39. Thut CJ, Chen JL, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science (1995) 267(5194):100-4. doi:10.1126/science.7809597.
40. Fukuchi J, Hiipakka RA, Kokontis JM, Nishimura K, Igarashi K, Liao S. TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis. J Biol Chem (2004) 279(29):29921-9. doi:10.1074/jbc.M401078200.
41. Munz C, Psichari E, Mandilis D, Lavigne AC, Spiliotaki M, Oehler T, et al. TAF7 (TAFII55) plays a role in the transcription activation by c-Jun. J Biol Chem (2003) 278(24):21510-6. doi:10.1074/jbc.M212764200.
42. Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH. Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol (2013) 30(1):368. doi:10.1007/s12032-012-0368-8.
43. Bosco-Clement G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, et al. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene (2013). doi:10.1038/onc.2013.164.
44. Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, Lozano G, et al. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene (2002) 21(46):7100-13. doi:10.1038/sj.onc.1205856.
45. Buschmann T, Lin Y, Aithmitti N, Fuchs SY, Lu H, Resnick-Silverman L, et al. Stabilization and activation of p53 by the coactivator protein TAFII31. J Biol Chem (2001) 276(17):13852-7. doi:10.1074/jbc.M007955200.
46. Lu H, Levine AJ. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 92(11):5154-8. doi:10.1073/pnas.92.11.5154.
47. Verrier CS, Roodi N, Yee CJ, Bailey LR, Jensen RA, Bustin M, et al. High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation. Mol Endocrinol (1997) 11(8):1009-19. doi:10.1210/mend.11.8.9962.
48. Voulgari A, Voskou S, Tora L, Davidson I, Sasazuki T, Shirasawa S, et al. TATA box-binding protein-associated factor 12 is important for RAS-induced transformation properties of colorectal cancer cells. Mol Cancer Res (2008) 6(6):1071-83. doi:10.1158/1541-7786.MCR-07-0375.
49. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474(7353):609-15. doi:10.1038/nature10166.
50. Brunkhorst A, Karlen M, Shi J, Mikolajczyk M, Nelson MA, Metsis M, et al. A specific role for the TFIID subunit TAF4 and RanBPM in neural progenitor differentiation. Mol Cell Neurosci (2005) 29(2):250-8. doi:10.1016/j.mcn.2005.02.015.
51. Indra AK, Mohan WS II, Frontini M, Scheer E, Messaddeq N, Metzger D, et al. TAF10 is required for the establishment of skin barrier function in foetal, but not in adult mouse epidermis. Dev Biol (2005) 285(1):28-37. doi:10.1016/j.ydbio.2005.05.043.
52. Iwata J, Hosokawa R, Sanchez-Lara PA, Urata M, Slavkin H, Chai Y. Transforming growth factor-beta regulates basal transcriptional regulatory machinery to control cell proliferation and differentiation in cranial neural crest-derived osteoprogenitor cells. J Biol Chem (2010) 285(7):4975-82. doi:10.1074/jbc.M109.035105.
53. D'Alessio JA, Ng R, Willenbring H, Tjian R. Core promoter recognition complex changes accompany liver development. Proc Natl Acad Sci U S A (2011) 108(10):3906-11. doi:10.1073/pnas.1100640108.
54. Liu Z, Scannell DR, Eisen MB, Tjian R. Control of embryonic stem cell lineage commitment by core promoter factor, TAF3. Cell (2011) 146(5):720-31. doi:10.1016/j.cell.2011.08.005.
55. Bahat A, Kedmi R, Gazit K, Richardo-Lax I, Ainbinder E, Dikstein R. TAF4b and TAF4 differentially regulate mouse embryonic stem cells maintenance and proliferation. Genes Cells (2013) 18(3):225-37. doi:10.1111/gtc.12030.
56. Mengus G, Fadloun A, Kobi D, Thibault C, Perletti L, Michel I, et al. TAF4 inactivation in embryonic fibroblasts activates TGF beta signalling and autocrine growth. EMBO J (2005) 24(15):2753-67. doi:10.1038/sj.emboj.7600748.
57. Pijnappel WW, Esch D, Baltissen MP, Wu G, Mischerikow N, Bergsma AJ, et al. A central role for TFIID in the pluripotent transcription circuitry. Nature (2013) 495(7442):516-9. doi:10.1038/nature11970.
58. Kazantseva J, Kivil A, Tints K, Kazantseva A, Neuman T, Palm K. Alternative splicing targeting the hTAF4-TAFH domain of TAF4 represses proliferation and accelerates chondrogenic differentiation of human mesenchymal stem cells. PLoS One (2013) 8(10):e74799. doi:10.1371/journal.pone.0074799.
59. Greene AK, Puder M. Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg (2003) 16(2):99-102. doi:10.1080/08941930390194424.
60. Tantin D, Gemberling M, Callister C, Fairbrother WG. High-throughput biochemical analysis of in vivo location data reveals novel distinct classes of POU5F1(Oct4)/DNA complexes. Genome Res (2008) 18(4):631-9. doi:10.1101/gr.072942.107.
61. Lovasco LA, Seymour KA, Zafra K, O'Brien CW, Schorl C, Freiman RN. Accelerated ovarian aging in the absence of the transcription regulator TAF4B in mice. Biol Reprod (2010) 82(1):23-34. doi:10.1095/biolreprod.109.077495.
62. Voronina E, Lovasco LA, Gyuris A, Baumgartner RA, Parlow AF, Freiman RN. Ovarian granulosa cell survival and proliferation requires the gonad-selective TFIID subunit TAF4b. Dev Biol (2007) 303(2):715-26. doi:10.1016/j.ydbio.2006.12.011.
63. Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol (2013) 130(1):246-51. doi:10.1016/j.ygyno.2013.03.021.
64. Dubeau L, Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol (2013) 24(Suppl 8):viii28-35. doi:10.1093/annonc/mdt308.
65. Giles JR, Shivaprasad HL, Johnson PA. Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma. Gynecol Oncol (2004) 95(3):530-3. doi:10.1016/j.ygyno.2004.07.061.
66. Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, et al. 17Beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology (2010) 151(3):929-38. doi:10.1210/en.2009-0602.
67. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 63(6):1389-97.
68. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res (2003) 63(13):3459-63.
69. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature (2013) 495(7440):241-5. doi:10.1038/nature11979.
70. Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, et al. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) (2009) 2(2):114-21. doi:10.1158/1940-6207.CAPR-08-0065.
71. Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis (1985) 3(4):257-79. doi:10.1007/BF01585081.
72. Sakuragi N, Nishiya M, Ikeda K, Ohkouch T, Furth EE, Hareyama H, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol (1994) 53(2):183-9. doi:10.1006/gyno.1994.1113.
73. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res (1991) 51(23 Pt 1):6328-37.
74. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol (1993) 142(4):987-93.
75. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer (2012) 118(12):3087-94. doi:10.1002/cncr.26618.
76. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, et al. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg (2001) 71(3):949-54. doi:10.1016/S0003-4975(00)02545-5.
77. Tamura S, Shiozaki H, Miyata M, Kadowaki T, Inoue M, Matsui S, et al. Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg (1996) 83(11):1608-14. doi:10.1002/bjs.1800831138.
78. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol (2003) 84(3):127-31. doi:10.1002/jso.10308.
79. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol (1996) 105(4):394-402.
80. Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets (2012) 13(13):1649-53. doi:10.2174/138945012803530044.
81. Borgfeldt C, Hansson SR, Gustavsson B, Masback A, Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer (2001) 92(4):497-502. doi:10.1002/ijc.1215.
82. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology (1998) 32(1):69-80. doi:10.1046/j.1365-2559.1998.00341.x.
83. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer (1994) 58(3):393-9. doi:10.1002/ijc.2910580315.
84. Fujioka T, Takebayashi Y, Kihana T, Kusanagi Y, Hamada K, Ochi H, et al. Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep (2001) 8(2):249-55.
85. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol (2003) 202(1-2):89-96. doi:10.1016/S0303-7207(03)00068-6.
86. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer (2003) 89(7):1298-304. doi:10.1038/sj.bjc.6601265.
87. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 68(11):4311-20. doi:10.1158/0008-5472.CAN-08-0364.
88. Wang ML, Chiou SH, Wu CW. Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther (2013) 6:1207-20. doi:10.2147/OTT.S38114.
89. Lopez J, Valdez-Morales FJ, Benitez-Bribiesca L, Cerbon M, Carranca AG. Normal and cancer stem cells of the human female reproductive system. Reprod Biol Endocrinol (2013) 11:53. doi:10.1186/1477-7827-11-53.
90. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 8(1):158-66. doi:10.4161/cc.8.1.7533.
91. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis (2012) 29(8):939-48. doi:10.1007/s10585-012-9482-4.
92. Yasuda K, Torigoe T, Morita R, Kuroda T, Takahashi A, Matsuzaki J, et al. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One (2013) 8(8):e68187. doi:10.1371/journal.pone.0068187.
93. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2012) 130(1):29-39. doi:10.1002/ijc.25967.
94. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 71(11):3991-4001. doi:10.1158/0008-5472.CAN-10-3175.
95. Metzger D, Scheer E, Soldatov A, Tora L. Mammalian TAF(II)30 is required for cell cycle progression and specific cellular differentiation programmes. EMBO J (1999) 18(17):4823-34. doi:10.1093/emboj/18.17.4823.
96. Chalkley GE, Verrijzer CP. DNA binding site selection by RNA polymerase II TAFs: a TAF(II)250-TAF(II)150 complex recognizes the initiator. EMBO J (1999) 18(17):4835-45. doi:10.1093/emboj/18.17.4835.
97. Martinez E, Zhou Q, L'Etoile ND, Oelgeschlager T, Berk AJ, Roeder RG. Core promoter-specific function of a mutant transcription factor TFIID defective in TATA-box binding. Proc Natl Acad Sci U S A (1995) 92(25):11864-8. doi:10.1073/pnas.92.25.11864.
98. Wright KJ, Marr MT II, Tjian R. TAF4 nucleates a core subcomplex of TFIID and mediates activated transcription from a TATA-less promoter. Proc Natl Acad Sci U S A (2006) 103(33):12347-52. doi:10.1073/pnas.0605499103.
99. Wieczorek E, Brand M, Jacq X, Tora L. Function of TAF(II)-containing complex without TBP in transcription by RNA polymerase II. Nature (1998) 393(6681):187-91. doi:10.1038/30283.
100. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, et al. Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res (2012) 18(21):5911-23. doi:10.1158/1078-0432.CCR-12-1257.
101. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 88(1):73-9. doi:10.1006/gyno.2002.6851.
102. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 101(7):2076-81. doi:10.1073/pnas.0308334100.
103. Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology (2012) 153(7):2953-62. doi:10.1210/en.2012-1061.
104. Johnson SA, Dubeau L, Kawalek M, Dervan A, Schonthal AH, Dang CV, et al. Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. Mol Cell Biol (2003) 23(9):3043-51. doi:10.1128/MCB.23.9.3043-3051.2003.
105. Soe KC, Devaiah BN, Singer DS. Transcriptional coactivator CIITA, a functional homolog of TAF1, has kinase activity. Biochim Biophys Acta (2013) 1829(11):1184-90. doi:10.1016/j.bbagrm.2013.09.001.
106. Sekiguchi T, Nishimoto T, Hunter T. Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation. Oncogene (1999) 18(10):1797-806. doi:10.1038/sj.onc.1202508.
107. O'Brien T, Tjian R. Functional analysis of the human TAFII250 N-terminal kinase domain. Mol Cell (1998) 1(6):905-11. doi:10.1016/S1097-2765(00)80089-1.
108. Falender AE, Shimada M, Lo YK, Richards JS. TAF4b, a TBP associated factor, is required for oocyte development and function. Dev Biol (2005) 288(2):405-19. doi:10.1016/j.ydbio.2005.09.038.
109. Wang C, Lv X, Jiang C, Cordes CM, Fu L, Lele SM, et al. Transforming growth factor alpha (TGFalpha) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways. PLoS One (2012) 7(11):e48299. doi:10.1371/journal.pone.0048299.
110. Geles KG, Freiman RN, Liu WL, Zheng S, Voronina E, Tjian R. Cell-type-selective induction of c-jun by TAF4b directs ovarian-specific transcription networks. Proc Natl Acad Sci U S A (2006) 103(8):2594-9. doi:10.1073/pnas.0510764103.
111. Liu WL, Coleman RA, Grob P, King DS, Florens L, Washburn MP, et al. Structural changes in TAF4b-TFIID correlate with promoter selectivity. Mol Cell (2008) 29(1):81-91. doi:10.1016/j.molcel.2007.11.003.
112. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev (2012) 33(1):109-44. doi:10.1210/er.2011-0014.
113. Gulliver LS, Hurst PR. Repeat estradiol exposure differentially regulates protein expression patterns for estrogen receptor and E-cadherin in older mouse ovarian surface epithelium: implications for replacement and adjuvant hormone therapies? Steroids (2012) 77(6):674-85. doi:10.1016/j.steroids.2012.02.015.
114. Okamura H, Katabuchi H, Nitta M, Ohtake H. Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology. Microsc Res Tech (2006) 69(6):469-81. doi:10.1002/jemt.20306.
115. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol (2002) 156(4):363-73. doi:10.1093/aje/kwf048.
116. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol (1998) 92(3):472-9. doi:10.1016/S0029-7844(98)00139-2.
117. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 288(3):334-41. doi:10.1001/jama.288.3.334.
118. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women's health initiative randomized trial. JAMA (2003) 290(13):1739-48. doi:10.1001/jama.290.13.1739.
119. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet (2007) 369(9574):1703-10. doi:10.1016/S0140-6736(07)60534-0.
120. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA (2001) 285(11):1460-5. doi:10.1001/jama.285.11.1460.
121. Yamit-Hezi A, Dikstein R. TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB. EMBO J (1998) 17(17):5161-9. doi:10.1093/emboj/17.17.5161.
122. Silkov A, Wolstein O, Shachar I, Dikstein R. Enhanced apoptosis of B and T lymphocytes in TAFII105 dominant-negative transgenic mice is linked to nuclear factor-kappa B. J Biol Chem (2002) 277(20):17821-9. doi:10.1074/jbc.M200696200.
123. Diamant G, Dikstein R. Transcriptional control by NF-kappaB: elongation in focus. Biochim Biophys Acta (2013) 1829(9):937-45. doi:10.1016/j.bbagrm.2013.04.007.
124. Aoki T, Koike T, Nakano T, Shibahara K, Nishimura H, Kikuchi H, et al. Rat TAFII31 gene is induced upon programmed cell death in differentiated PC12 cells deprived of NGF. Biochem Biophys Res Commun (1997) 234(1):230-4. doi:10.1006/bbrc.1997.6610.
125. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 16(5):267-82. doi:10.1097/PAP.0b013e3181b4fffa.
126. Tan DS, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer (2013) 108(8):1553-9. doi:10.1038/bjc.2013.126.
127. Davidson I, Kobi D, Fadloun A, Mengus G. New insights into TAFs as regulators of cell cycle and signaling pathways. Cell Cycle (2005) 4(11):1486-90. doi:10.4161/cc.4.11.2120.
128. Comai L, Tanese N, Tjian R. The TATA-binding protein and associated factors are integral components of the RNA polymerase I transcription factor, SL1. Cell (1992) 68(5):965-76. doi:10.1016/0092-8674(92)90039-F.
129. Taggart AK, Fisher TS, Pugh BF. The TATA-binding protein and associated factors are components of pol III transcription factor TFIIIB. Cell (1992) 71(6):1015-28. doi:10.1016/0092-8674(92)90396-T.
130. Johnson SA, Dubeau L, White RJ, Johnson DL. The TATA-binding protein as a regulator of cellular transformation. Cell Cycle (2003) 2(5):442-4. doi:10.4161/cc.2.5.493.